Obesity-Associated Alterations in Inflammation, Epigenetics, and Mammary Tumor Growth Persist in Formerly Obese Mice by Rossi, Emily L. et al.
Obesity-associated alterations in inflammation, epigenetics and 
mammary tumor growth persist in formerly obese mice
Emily L. Rossi1, Rebecca E. de Angel2, Laura W. Bowers1, Subreen A. Khatib1, Laura A. 
Smith1, Eric Van Buren3, Priya Bhardwaj4, Dilip Giri5, Marcos R. Estecio6, Melissa A. 
Troester7, Brionna Y. Hair7, Erin L. Kirk7, Ting Gong6, Jianjun Shen6, Andrew J. 
Dannenberg4, and Stephen D. Hursting1,2
1Department of Nutrition, University of North Carolina, Chapel Hill, NC 27599
2Department of Nutritional Sciences, University of Texas, Austin, TX 78712
3Department of Biostatistics, University of North Carolina, Chapel Hill, NC 27599
4Department of Medicine, Weill Cornell Medical College, New York, NY 10065
5Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065
6Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson 
Cancer Center, Houston, TX 77030
7Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599
Abstract
Using a murine model of basal-like breast cancer, we tested the hypothesis that chronic obesity, an 
established breast cancer risk and progression factor in women, induces mammary gland 
epigenetic reprogramming and increases mammary tumor growth. Moreover, we assessed whether 
the obesity-induced epigenetic and protumor effects are reversed by weight normalization. 
Ovariectomized female C57BL/6 mice were fed a control diet or diet-induced obesity (DIO) 
regimen for 17 weeks, resulting in a normal weight or obese phenotype, respectively. Mice on the 
DIO regimen were then randomized to continue the DIO diet or were switched to the control diet, 
resulting in formerly obese (FOb) mice with weights comparable to control mice. At week 24, all 
mice were orthotopically injected with MMTV-Wnt-1 mouse mammary tumor cells. Mean tumor 
volume, serum IL-6 levels, expression of pro-inflammatory genes in the mammary fat pad, and 
mammary DNA methylation profiles were similar in DIO and FOb mice, and higher than in 
controls. Many of the genes found to have obesity-associated hypermethylation in mice were also 
found to be hypermethylated in the normal breast tissue of obese versus non-obese human 
subjects, and nearly all of these concordant genes remained hypermethylated after significant 
weight loss in the FOb mice. Our findings suggest that weight normalization may not be sufficient 
to reverse the effects of chronic obesity on epigenetic reprogramming and inflammatory signals in 
the microenvironment that are associated with breast cancer progression.
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Introduction
Obesity is highly prevalent in the United States and many other parts of the world and is an 
established risk and progression factor for several intrinsic subtypes of breast cancer, 
including basal-like breast cancer (BLBC), in postmenopausal women (1). Greater rates of 
metastatic breast cancer and increased mortality are seen in the obese breast cancer patient 
population, independent of disease stage at diagnosis (2, 3). These effects may be mediated 
in part by adipose tissue inflammation, as excess adipose tissue results in local as well as 
systemic effects. Obesity is typically accompanied by increased systemic levels of pro-
inflammatory mediators, such as interleukin-6 (IL-6), tumor necrosis factor alpha (TNFα), 
matrix metalloproteinase-9 (MMP-9) and interleukin-1 beta (IL-1β), and these can 
independently influence tumor growth. In addition, obesity enhances the secretion of 
monocyte chemoattractant protein-1 (MCP-1), which stimulates the recruitment of 
macrophages to adipose tissue, including the breast adipose. These tumor-associated 
macrophages likely contribute to tumor growth by increasing local and/or systemic 
inflammatory and angiogenic factors and generating reactive oxygen species (4, 5).
In obese mice, calorie restriction reduces mammary tissue expression of several mediators of 
inflammation including TNFα and IL-1β (6). Less is known about the effects of obesity or 
weight loss interventions on the epigenome. There is mounting evidence that DNA 
methylation can be affected by energy balance. For example, weight loss interventions (30% 
energy reduction) in obese male subjects have been shown to induce DNA methylation 
changes at the TNFα promoter after only 8 weeks of diet intervention (7). In another study, 
severe weight loss after gastric bypass surgery in obese humans normalized methylation in 
the promoter regions of 11 out of 14 metabolic genes that had been dysregulated by obesity 
(8). Expression of the EZH2 gene, which encodes the epigenetic regulator histone-lysine-N-
methyltransferase, has been linked to breast cancer growth and metastasis (9). It is also 
modulated in the offspring of obese mothers (10), suggesting that this enzyme may mediate 
some of the effects of energy balance on epigenetic regulation. Although DNA methylation 
patterns are energy responsive, the relationship between weight loss, aberrant DNA 
methylation, adipose tissue inflammation, and cancer progression are unknown.
Epidemiological and preclinical studies have clearly shown that the metabolic perturbations 
typically accompanying obesity promote breast cancer progression (11). One study in 
particular illustrated how women who underwent bariatric surgery had a 5% reduction in 
incidence of breast cancer after 5 years of follow up from surgery compared to women who 
did not undergo a weight loss intervention- surgical or otherwise (12). However, with the 
exception of bariatric surgery interventions, the impact of intentional obesity reversal prior 
to diagnosis has not been well-established. The epidemiologic data have been mixed 
regarding non-surgically induced weight loss, reflecting the difficulties in achieving and 
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maintaining meaningful weight loss. Despite their limitations, animal model studies may be 
informative in addressing this question given their benefit of greater control of diet, physical 
activity and numerous other confounding variables. Sundaram et al. (2014) found that a 
high-fat diet promotes mammary tumor progression in a transgenic mouse model of BLBC, 
and switching mice to a low-fat diet after a short-term high-fat diet exposure led to small but 
statistically significant weight loss and reversed many of the high-fat diet effects on tumor 
progression to that of control levels (13). However, the transgenic mouse model used in this 
study were resistant to obesity induction, and tumors arose early in life, so the question of 
whether the mammary tumor-promoting effects of chronic obesity are reversed by weight 
loss was not addressed. We have previously found in a mouse model of chronic obesity, as 
well as in clinical studies of obese women, that a severe weight loss intervention may 
provide an anti-cancer benefit, but moderate weight loss had minimal effects on cancer-
related biomarkers in mice and women and tumor growth in mice (14, 15).
Given the uncertainty regarding the benefits of obesity reversal, we sought to determine the 
effects of weight loss on the host microenvironment and tumor progression in an orthotopic 
transplant model of murine BLBC in syngeneic mice. Here we demonstrate that tumor 
growth did not change with significant weight loss prior to orthotopic tumor transplant, 
despite the normalization of several obesity-related hormones. Moreover, we provide 
evidence that breast tumor growth after obesity reversal may be driven by epigenetic 
dysregulation in the microenvironment as well as sustained elevations in inflammatory 
signaling. These findings suggest that short-term weight loss may not reverse the tumor-
promoting epigenetic reprogramming and increased inflammatory signaling that 
accompanies chronic obesity.
Materials and Methods
Mice and Diets
All animal protocols were approved by the University of Texas at Austin Institutional 
Animal Care and Use Committee (IACUC) and carried out in compliance with all guidelines 
and regulations. Six-week-old female ovariectomized C57BL/6 mice were obtained from 
Charles River Laboratories, Inc. (Frederick, MD), individually housed on a 12-hour light/
dark cycle, and consumed food and water ad libitum. Food intake was measured twice a 
week and body weights were measured weekly. Mice were randomized to continue on the 
control diet (n=17) or a 60% kcal from fat diet-induced obesity (DIO) diet regimen (n=34; 
D12492, Research Diets, Inc.). After 17 weeks on diet, the DIO mice were randomized to 
either continue on the DIO regimen (DIO, n=17) or switch to the control diet to induce 
gradual weight loss; this latter group is referred to as formerly obese (FOb, n=17). After 24 
weeks on diet, 5 mice per group were fasted for 6–8 hours and then euthanized for pre-tumor 
tissue collection. The remaining mice (n=15/group) were orthotopically injected with 5×104 
syngeneic viable MMTV-Wnt-1 mammary tumor cells as previously described (16). In vivo 
growth was measured twice/week with skinfold calipers, and in vivo tumor area was 
approximated using the formula πr2. At study endpoint (week 36), mice were euthanized and 
mammary tumors, tumor-adjacent and tumor-distal mammary fat pad were excised and 
divided in portions to be formalin fixed or flash frozen in liquid nitrogen and stored at 
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−80°C until further analysis. Mice were excluded if they had developed dermatitis during 
study (one DIO mouse and one FOb mouse). Ex vivo tumor volume was calculated using the 
formula 4/3π × R12 × R2, (with R1 denoting the smaller radius of the ellipsoid) (17).
Quantitative Magnetic Resonance Analysis
Body composition was measured on all mice at weeks 17 and 24 of diet treatments by 
quantitative magnetic resonance (qMR) (Echo Medical Systems, Houston, TX). 
Measurements included lean mass, fat mass and total water mass. Percent body fat was 
calculated by dividing fat mass by total body weight.
Serum Hormone, Cytokine and Adipokine Measurement
Serum was collected from mice fasted 6–8 hours, prior to tumor cell injection (week 24) by 
retro-orbital bleed. Serum hormones, adipokines, and cytokines, including leptin, 
adiponectin, insulin, and IL-6, were measured using mouse adipokine 
LINCOplex®Multiplex Assays (Millipore, Inc., Billerica, MA) and analyzed on a BioRad 
Bioplex 200 analysis system (Biorad, Inc., Hercules, CA). Insulin-like growth factor 1 
(IGF-1) concentrations were measured using a Millipore Milliplex Rat/Mouse IGF-1 Single 
Plex assay (Millipore, Inc.).
Crown-like Structure Analysis
Four micron-thick sections were prepared from formalin-fixed, paraffin-embedded 
mammary fat pad tissue and stained with hematoxylin and eosin. The total number of CLS 
per section was quantified by a pathologist, blind to the sample group, and the amount of 
adipose tissue present on each slide was determined using NIH Image J. Prevalence of CLS 
was quantified as CLS per cm2 of adipose tissue.
Quantification of Adipocyte Infiltration in Tumor Tissue
Four micron-thick sections were prepared from formalin-fixed, paraffin-embedded tumor 
tissue and stained with hematoxylin and eosin. Tumors were chosen at random (4–5/group) 
and digitally imaged under 20× magnification. The total number of adipocytes per section 
(2–4 representative sections, each 830 µm × 580 µm) was quantified independently by 3 
investigators who were blinded to experimental group.
Quantitative RT-PCR
Total RNA was extracted from the flash-frozen tumor-adjacent and tumor-distal mammary 
fat pad samples collected at end of study using TRI-Reagent (Sigma-Aldrich, St.Louis, MO) 
according to manufacturer’s instructions. RNA concentration was spectrophotometrically 
determined using a nanodrop (Thermo Scientific, Logan, UT) and quality was confirmed 
using an Agilent 2100 Bioanalyzer (Santa Clara, CA). RNA was reverse transcribed with 
Multiscribe RT (Applied Biosystems, Carlsbad, CA). Resulting cDNA from tissue samples 
were assayed in triplicate for PCR using Taqman® Gene Expression Assays for IL-6, TNFα, 
MMP-9, IL-1β, IGFBP6, CITED1, TFE3, JAK3, EZH2, SMYD3, and TSC22D3 (Applied 
Biosystems). PCR reactions were completed using a ViiATM7 Real time PCR system 
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(Applied Biosciences). Gene expression data were normalized to the housekeeping gene β-
actin and analyzed using the delta delta cycle threshold method (18).
Methylation Analysis
DNA was extracted from the 9th tumor-distal mammary fat pad, at end of study (n=3/group) 
using UltraPure™ Phenol:Chloroform:Isoamyl Alcohol per manufacturer’s instructions 
(Life Technologies, Carlsbad, CA). Genome-wide methylation profiles for mammary fat pad 
from control, DIO and FOb mice were determined by RRBS (Reduced Representation 
Bisulfite Sequencing). Among the available methods for genome-wide analysis of the DNA 
methylation, we selected RRBS based in its compatibility and validation with mouse DNA, 
its capacity to investigate individual sites by bisulfite-sequencing, and the large number 
(above 400 thousand) of CpG sites that are evaluated in a single experiment. Library 
preparation and sequencing were completed at the UT MD Anderson Cancer Center’s DNA 
Methylation Analysis Core and Science Park Next-Generation Sequencing Facility, 
according to published protocols (19, 20) (Supplementary Table S3). Briefly, 1ug of 
genomic DNA was digested with MspI, a methylation-insensitive enzyme that cleaves the 
DNA at CCGG sequences, followed by end-repair, A-tailing and size selection. Enrichment 
for CpG sites in CG-dense and CpG islands is achieved by selective collection and PCR 
amplification of MspI fragments with sizes between 40bp and 170bp.Sequence reads were 
mapped to the mouse genome (mm10) using Bismark bisulfite read mapper. The location of 
individual CpG sites in relationship to known genes was based on the mm10 RefSeq gene 
annotations and classified as promoter (CpG sites 1 kb upstream of the annotated 
transcription start site (TSS) and extending 500 base pairs downstream of TSS), exon, 
intron, or CpG island. CpG island coordinates were collected from the UCSC Genome 
Browser mm10 version, Genome Reference Consortium GRCm38. Differential methylation 
was calculated by filtering samples based on read coverage ≥ 20, then performed at the 
single base level independent of the CpG site location. TSS of transcripts smaller than 300 
bp were removed for the analysis. Methylkit R package was used to apply logistic regression 
and the likelihood ratio test. Observed p-values were adjusted with the success likelihood 
index method (SLIM).
Selection of Samples from the Normal Breast Study for Methylation Analysis
Selection criteria for the Normal Breast Study included having an invasive ductal carcinoma 
with a tissue specimen sampled ≥4 cm from tumor margins, undergoing reduction 
mammoplasty, or undergoing prophylactic surgery (21). There were 150 participants with 
invasive breast cancer had tissue collected that was >4 cm from the tumor. Participants were 
randomly selected from each BMI group: 30 from the high BMI (>30), 20 from the normal 
BMI (25–30), and 22 from the low BMI (<25) group. All prophylactics and reduction 
participants were also included. In all, 96 participants were selected. All tissue specimens 
were snap frozen. A 50 mg sample was taken from the participants’ tissue specimens and 
used for methylation assessment. The University of North Carolina at Chapel Hill 
Institutional Review Board approved this study.
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DNA Extraction from Human Breast Samples
DNA was isolated using the DNeasy Blood and Tissue kit from Qiagen (Venlo, Netherlands) 
following the manufacturer’s protocol. Sodium bisulfite modification of the DNA was 
conducted using EZ DNA Methylation Gold Kit (Zymo Research, Orange, CA), and 500 ng 
of DNA was used for the HumanMethylation450 BeadChip platform. The samples were 
processed for DNA methylation analysis by the University of North Carolina at Chapel 
Hill’s Mammalian Genotyping Core.
Concordance Between Mouse and Human Genes Methylated in Response to Energy 
Balance Modulation
We compared our mouse methylation dataset with a dataset obtained from the University of 
North Carolina Normal Breast Study utilizing non-tumorous breast tissue, subject to 
methylation array and stratified by BMI. A methylation difference was calculated for each 
significant methylation change (obese vs. non-obese) with a positive coefficient signifying 
increasing methylation with increased adiposity. Intraspecies concordance was assayed only 
for genes with significant differences within species (Supplementary Table S2). Welch’s t-
test was used for the pairwise comparisons between obese and non-obese humans using R 
version 3.1.2 (http://www.r-project.org). Comparisons between both species was done by 
one-way analysis of variance (ANOVA) using GraphPad Prism V6 with Bonferroni 
correction for multiple comparisons.
Statistical Analysis
Values are presented as mean ± standard deviation (SD). One-way ANOVA using Tukey’s 
multiple comparisons correction was used to assess the effects of diet treatment on body 
weight and fat percentage, mean tumor size, serum hormone and cytokine concentrations, 
and mammary fat pad gene expression. Student’s t-test was used to compare differences in 
CLS between experimental groups and control. For all tests, GraphPad Prism software was 
used (GraphPad Software Inc., La Jolla, CA), and P ≤ 0.05 was considered statistically 
significant.
Results
Body Weight and Body Composition of Control, DIO, and FOb mice
Mice were fed a low-fat control or a diet-induced obesity (DIO) regimen for 17 weeks, at 
which time percent body fat, assessed by quantitative resonance analysis, was higher in DIO 
mice (59.7 ± 1.8%) compared to control mice (39.5 ± 4.0%) (P < 0.001; Fig. 1A). DIO mice 
also had a higher mean body weight (51.5 ± 0.7 g) than control mice (33.1 ± 0.7 g) (Fig. 
1B). After weight loss was initiated at week 17, FOb mice lost 27.6 ± 3.4% of their body 
weight (14.2 ± 1.7 g) (P < 0.0001) relative to their last weight taken while on the DIO diet. 
By week 24, the body fat percentage in FOb mice (45.1 ± 3.5%) did not significantly differ 
from mice maintained on the control diet throughout study (42.6 ± 3.3%), with DIO mice 
(60.1 ± 1.5%) having significantly greater body fat percentage than control and FOb mice (P 
< 0.001; Fig. 1A). FOb and control mice maintained significantly lower body weights than 
DIO mice through the end of study (P < 0.0001, Fig. 1B).
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Effect of Weight Loss on Serum Metabolic and Inflammatory Markers
Serum was collected from mice at week 24 by retro-orbital bleed, prior to tumor cell 
injection and when the body weights of the FOb mice were statistically equivalent to the 
control mice. The reduction in adiposity in the FOb mice was accompanied by lower serum 
leptin (P < 0.0001), leptin:adiponectin ratio (P < 0.0001), and insulin (P < 0.0001) relative to 
DIO mice (Fig. 1C–E), with concentrations statistically equivalent to those found in the 
control mice. IGF-1 levels were significantly higher in DIO mice relative to control (P < 
0.05; Fig. 1G) but were intermediate in FOb mice and not statistically different from the 
levels seen in control or DIO mice. Furthermore, IL-6 levels did not differ between FOb and 
DIO mice and were significantly elevated in both groups compared to control mice (P < 
0.05; Fig. 1H).
Weight Loss in FOb Mice Reduced Prevalence of Crown-like Structures (CLS)
The high-fat dietary regimen increased the prevalence of CLS (expressed as CLS / area of 
tissue in cm2) in the mammary fat pad of DIO mice relative to control mice (P < 0.003; Fig. 
2). This was analyzed in tissue harvested at the interim (week 24) time point. FOb mice had 
a significant reduction in CLS compared to DIO mice (P < 0.03); however, prevalence of 
CLS remained slightly elevated relative to control, though this difference was not 
statistically significant (P = 0.4).
Weight Loss in FOb Mice Does Not Decrease Basal-like Mammary Tumor Burden
Ex vivo tumor volume from DIO and FOb mice were larger (1792.7± 1132.9 mm3, 1563.4 
± 1673.3 mm3, respectively) than tumors from the control mice (51.6 ± 139.8 mm3) (P < 
0.05; Fig. 3A). Furthermore, a shared attribute of tumors from both the DIO and FOb groups 
were the presence of adipose cells infiltrating the tumor in greater number compared to 
control (Fig. 3B). Tumors from DIO mice contained a significantly higher number of 
adipocytes than control tumors (168.4 ± 83.4 adipocytes / mm2 and 34.6 ± 32.2 adipocytes / 
mm2, respectively; P < 0.05). Tumors in FOb mice had an intermediate level of adipocyte 
infiltration (127.1 ± 83.6 adipocytes/mm2) that did not significantly differ from either 
control (P = 0.19) or DIO (P = 0.66). Collectively, these findings suggest that significant 
weight loss does not completely reverse the effects of obesity on BLBC growth and 
adipocyte-infiltration.
Pro-Inflammatory Cytokine Gene Expression is Elevated in Mammary Fat Pad from FOb 
Mice
RT-PCR analysis was performed on tumor-distal mammary fat pad (n=4–5 mice). Relative to 
control, FOb mice had significantly elevated IL-6 expression (P < 0.001, Fig. 4A), with DIO 
mice having non-significantly elevated levels relative to control. TNFα expression was 
significantly elevated in DIO (P < 0.04) and FOb (P < 0.03; Fig 4B) versus control mice. 
MMP-9 expression was greater in FOb mice (P < 0.05; Fig. 4C), with DIO mice 
experiencing an intermediate increase compared to control. IL1-® expression was 
significantly higher in FOb and DIO mice (P < 0.01; Fig. 4D) compared to control.
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Weight Loss Fails to Normalize Obesity-induced Hypermethylation Patterns and Histone 
Methyltransferase Enzymes EZH2 and SMYD3 in Mammary Fat Pad
To determine whether the sustained elevation in tumor growth observed in FOb mice may be 
mediated in part by epigenetic reprogramming in the microenvironment, we assessed the 
global DNA methylation pattern of the tumor-distal mammary fat pad at end of study. DIO 
mice had 39 genes significantly hypermethylated compared to control. Of these 39 
differentially methylated genes, FOb mice generally possessed intermediate levels of 
methylation relative to control and DIO mice, suggesting that weight reduction back to 
control levels was insufficient to completely reverse the epigenetic reprogramming that 
occurs with chronic obesity (Fig. 5A). FOb mice had 11 genes significantly hypermethylated 
compared to control. While the methylation levels of these genes were also elevated in DIO 
mice, they were not significantly different from control
Hypermethylated genes in DIO and FOb mice relative to control were entered into Qiagen’s 
Ingenuity® Pathway Analysis (IPA) to delineate pathological signaling pathways. Gene 
expression was confirmed on a select number of genes (Fig. 5B–H). IPA Biofunction 
analysis connected the genes from our methylation analysis to a disease or biological 
function. Cancer was the primary disease with 23 genes hypermethylated in DIO (22 of the 
genes) or DIO and FOb (1 gene) implicated in cancer, specifically neoplasia of epithelial 
tissue (Supplementary Table S1). Another biofunction with 17 genes associated with it was 
cellular growth and proliferation. Four genes in our data set were identified as playing a role 
in cell-mediated immune response. Significant overlap of differentially methylated genes in 
DIO or FOb mice with each biofunction was determined by Fisher’s exact test.
We moved forward with genes that appeared in the IPA Biofunction of cancer with a 
function of neoplasia of epithelial tissue (IGFBP6, SMYD3, and JAK3) and transcription 
factor TSC22D3 and investigated their role as regulators in inflammatory signaling, with 
particular interest in the relationship between each gene and IL-6 (Supplementary Figure S1) 
As stated previously, IL-6 serum (Fig. 1H) and tumor-distal mammary fat pad mRNA levels 
(Fig. 4A) were elevated in DIO and FOb mice relative to controls. Of note, inhibitors of IL-6 
including TSC22D3 (intron) and JAK3 (exon) were hypermethylated. EZH2 was also 
predicted by the IPA analysis to be regulated by these genes, and expression of EZH2 in 
tumor-distal mammary fat pad of endpoint animals was significantly higher in DIO (P < 
0.05) and FOb (P < 0.005) mice compared to control mice (Fig. 5H). The gene for another 
methyltransferase enzyme, SET and MYND domain-containing protein 3 (SMYD3), was 
also identified as differentially methylated in our analysis, and its expression in tumor-distal 
mammary fat pad was significantly elevated in FOb mice (P < 0.02), with DIO mice having 
non-significantly elevated levels.
Hypermethylation Concordance in Mammary Tissue from Non-obese and Obese Humans 
and Mice
After we identified a panel of genes that were significantly hypermethylated in the 
mammary fat pad of DIO mice compared to controls, we assessed the methylation status of 
this gene panel in a methylation data set from normal human breast tissue involving subjects 
stratified by body mass index (BMI) (Supplementary Table S2). Thirteen genes were 
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identified with concordant hypermethylation (% methylation difference with the same 
directionality) in DNA from normal mammary tissue at the same genomic feature (i.e. intron 
vs. exon) in obese vs. non-obese women and mice (Table 1). However, as some significant 
methylation changes mapped to the same gene, of the 13 concordant genes, 6 had additional 
discordant methylation sites. We also identified an additional 3 genes with only discordant 
methylation between species. We then compared methylation (as % methylated DNA) for 
CpG’s related to the same gene in the same genomic feature (i.e. intron or exon) between 
women and mice. Non-obese women and control fed mice had levels of DNA methylation 
that were statistically equivalent for 4 of the 13 concordant genes identified. Of the 13 
hypermethylated genes in obese women and DIO mice, 6 genes reached statistical 
equivalence (CDK2AP1, CYFIP1, MAF, MAML3, SH3PXD2A, SMYD3). Of those 4 were 
statistically equivalent in obese women, DIO mice, and FOb mice. Seven genes were 
significantly different between obese humans and DIO mice due to varying degrees of 
hypermethylation.
Discussion
In our orthotopic tumor transplant model of BLBC in C57BL/6 mice, we found that DIO, 
relative to control diet, elevated: a) body fat percentage; b) serum leptin, leptin:adiponectin 
ratio, insulin, IGF-1, and IL-6; c) prevalence of CLS in mammary fat pad; d) mammary 
tumor growth; and e) genome-wide mammary gland hypermethylation. Significant weight 
loss initiated after 17 weeks on DIO diet resulted in a normalization of percent body fat and 
serum leptin, leptin:adiponectin, insulin levels, and prevalence of CLS in mammary fat pad 
in the FOb mice. Serum IGF-1 decreased to levels intermediate to DIO and control levels. 
Despite these beneficial metabolic changes and weight normalization, FOb mice had a final 
tumor volume nearly identical to DIO mice. Additionally, we observed that obesity reversal 
in the FOb mice failed to normalize serum IL-6 and mammary fat pad inflammatory gene 
expression as well as aberrant methylation in the mammary gland, and these may contribute 
to the persistence of the pro-cancer effects of obesity even after weight is normalized. We 
have identified several genes with concordant obesity-related hypermethylation in humans 
and mice, and the DNA methylation levels of many of these genes were unchanged after 
significant weight loss in the FOb mice, providing further support that obesity-associated 
epigenetic reprogramming may not be easily reversed with weight normalization alone.
To our knowledge, this is the first study to: i) characterize the effects of obesity reversal on 
mammary gland microenvironment (including DNA methylation) and tumor growth; ii) 
identify genes with concordant and discordant obesity-related methylation patterns in 
normal mammary tissue from mice and humans. We and others have previously found that a 
severe weight loss intervention, or inhibiting the mTOR signaling pathway in obese mice 
using genetic or pharmacologic approaches (18, 22, 23), decreases murine mammary tumor 
progression. Severe weight loss in humans, such as that achieved by bariatric surgery, has 
also shown the ability to significantly decrease inflammatory signaling (24), DNA 
hypermethylation (8), and cancer risk (12, 25). However, the weight loss that was achieved 
in our study via an ad libitum low-fat diet, which models many human weight loss plans, 
failed to reduce inflammatory signaling and elevated methylation levels in the FOb mice.
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Inflammation is implicated in many of the deleterious effects of obesity (26, 27). In the 
present study, weight loss in FOb mice normalized metabolic regulators that are elevated in 
obesity such as serum leptin:adiponectin, insulin, and adipose tissue CLS. However, several 
measures of inflammation persisted after weight loss, including serum IL-6 and gene 
expression of inflammatory cytokines in the mammary tissue. Thus, we are able to 
distinguish the pro-cancer effects of obesity-related metabolic perturbations from obesity-
related inflammation, which persists after weight loss.
We also found evidence suggesting that obesity-induced aberrant hypermethylation 
contributes to the maintenance of a pro-inflammatory, pro-growth microenvironment in the 
mammary fat pad of mice, and this is not normalized by significant weight loss. Abnormal 
expression of EZH2 plays a role in cancer growth and metastasis in a variety of cancers, 
including breast (28). A high-density tissue microarray analysis of breast tumors from 280 
patients revealed that EZH2 levels were increased in patients with invasive breast carcinoma 
relative to patients with no lesions or atypical hyperplasia (29). Additionally, EZH2 
increases expression of SMYD3, a histone H3 lysine-4 specific methyltransferase, which 
plays a key role in the proliferation and migration of several cancers. Cell culture studies 
have shown that silencing of SMYD3 by siRNA inhibits growth of breast cancer cells (30). 
We demonstrated here that both EZH2 and SMYD3 expression remained elevated in the 
mammary fat pad tissue of FOb mice, similar to the DIO group, indicating that these 
epigenetic regulators may be involved in mediating the mammary tumor-promoting effects 
of obesity.
Study limitations include the lack of a time course, since it is plausible that FOb mice could 
have had decreased tumor growth if challenged after a longer period of weight 
normalization. Additionally, as serum IL-6, mammary fat pad inflammatory gene 
expression, and mammary fat pad methylation all remained elevated in FOb mice compared 
to control, we are unable to delineate the individual contribution of each factor to the 
increased tumor burden. As expected, many but not all methylation changes investigated 
resulted in a corresponding change in gene expression. This is likely influenced by distance 
between the site of methylation change and promoter region, influence of chromatin 
features, or multiple systemic levels of regulation at play (31, 32).
The results of our study raise important questions concerning the relationship between 
obesity and the progression of more aggressive breast cancers such as the basal type. 
Numerous studies have shown that obesity is associated with increased risk of mortality 
from breast cancer (33). As weight loss did not suppress tumor progression in mice that had 
at one time been obese, further research is needed to investigate a potential critical window 
regarding the timing and magnitude of weight loss to achieve an anti-tumor effect. Future 
studies should also explore weight loss in combination with adjuvant therapy, such as 
prophylactic NSAID use to combat inflammation. The hypermethylation observed in DIO 
and FOb mice may also provide a new druggable target for breaking the obesity-breast 
cancer link. In summary, we found that MMTV-Wnt-1 mammary tumor growth was similar 
in DIO and FOb mice, with both groups exhibiting larger tumors than control mice. DNA 
methylation in the tumor-distal mammary fat pad at study endpoint was also significantly 
elevated in DIO mice relative to control, with FOb mice possessing intermediate DNA 
Rossi et al. Page 10
Cancer Prev Res (Phila). Author manuscript; available in PMC 2017 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
methylation levels. This is particularly surprising considering that at the time of tumor cell 
injection, FOb mice did not differ from control mice in terms of body weight, body 
composition, and serum metabolic markers of obesity, with the exception of serum IL-6. 
Taken together, our findings suggest a relationship between chronic obesity, the epigenome, 
inflammation and mammary cancer. Consequently, a combination of weight loss and 
epigenetic or anti-inflammatory interventions may be required to effectively break the 
obesity-breast cancer link.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
(A) Percent body fat mass in Control versus Obese mice at Week 17 on diet and in Control, 
Formerly obese, and Obese mice at Week 24. (B) Body weight in the three diet groups over 
the course of the study. Different letters indicate significant differences, P<0.05. Serum 
levels of several hormones, growth factors, and adipokines were measured in mice from all 
three diet groups at Week 24 of study, including (C) leptin, (D) leptin:adiponectin ratio, (E) 
insulin, (F) adiponectin, (G) IGF-1, (H) IL-6. Different letters indicate significant 
differences, P<0.05.
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Figure 2. 
Mouse mammary fat pad tissue at week 24 on diet was assessed for the prevalence of (A) 
crown-like structures (CLS) using H & E stained tissue sections, representative image 
shown. (B) CLS were quantified for each tissue sample as number of CLS per cm2. Different 
letters indicate significant differences, P < 0.05.
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Figure 3. 
(A) Ex vivo tumor volume at end of study. (B) Differing levels of adipocyte infiltration into 
the tumor tissue of mice from the three diet groups. Different letters indicate significant 
differences, P < 0.05.
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Figure 4. 
mRNA expression of pro-inflammatory genes was measured in the tumor-distal mammary 
fat pad of mice sacrificed at end of study, including (A) IL-6; (B) TNFα; (C) MMP-9; (D) 
IL-1β. Different letters indicate significant differences, P < 0.05.
Rossi et al. Page 17
Cancer Prev Res (Phila). Author manuscript; available in PMC 2017 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 5. 
(A) Heat map representation of gene methylation values expressed as % methylated DNA. 
Corresponding gene expression of (B) IGFBP6, (C) CITED1, (D) TFE3, (E) JAK3, (F) 
SMYD3 and (G) TSC22D3 in tumor-distal mammary fat pad. Additional expression shown 
for implicated genes (H) EZH2. Different letters indicate significant differences, P < 0.05.
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